摘要
目的:探讨双歧杆菌四联活菌片联合洛哌丁胺治疗腹泻型肠易激综合征(IBS-D)患者的效果。方法:选取2021年1月至2023年1月该院收治的70例IBS-D患者进行前瞻性研究,按随机数字表法将其分为对照组和观察组各35例。对照组口服洛哌丁胺胶囊治疗,观察组在对照组基础上口服双歧杆菌四联活菌片治疗。比较两组临床疗效,治疗前后血清炎性因子[白细胞介素(IL)-2、IL-6及肿瘤坏死因子-α(TNF-α)]水平、临床症状积分、肠道菌群数量,以及不良反应发生率。结果:观察组治疗总有效率为97.14%(34/35),高于对照组的77.14%(27/35),差异有统计学意义(P<0.05);治疗后,观察组腹痛、腹胀、大便性状、大便次数积分及血清IL-2、IL-6及TNF-α水平均低于对照组,双歧杆菌、乳杆菌数量均多于对照组,肠杆菌、肠球菌数量均少于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:双歧杆菌四联活菌片联合洛哌丁胺治疗IBS-D患者效果确切,可加快症状缓解,恢复肠道菌群平衡,降低炎性因子水平,效果优于单用洛哌丁胺治疗。
Objective:To investigate effects of Bifidobacterium quadruple viable tablets combined with Loperamide in treatment of patients with diarrhea-predominant irritable bowel syndrome(IBS-D).Methods:A prospective study was conducted on 70 patients with IBS-D admitted to this hospital from January 2021 to January 2023.According to the random number table method,they were divided into control group and observation group,35 cases in each group.The control group was treated with oral Loperamide capsules,while the observation group was treated with oral Bifidobacterium quadruple viable tablets on the basis of that of the control group.The clinical efficacy,the levels of serum inflammatory factors[interleukin(IL)-2,IL-6 and tumor necrosis factor-α(TNF-α)],the clinical symptom scores and the number of intestinal flora before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 97.14%(34/35),which was higher than 77.14%(27/35)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the scores of abdominal pain,abdominal distension,stool traits,stool frequency and the serum IL-2,IL-6 and TNF-αlevels in the observation group were lower than those in the control group,the number of Bifidobacteria and Lactobacilli were higher than those in the control group,the number of Enterobacteria and Enterococcus were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Bifidobacterium quadruple viable tablets combined with Loperamide is effective in the treatment of the IBS-D patients,which can accelerate the symptom relief,restore the balance of intestinal flora and reduce the levels of inflammatory factors.Moreover,it is superior to single Loperamide treatment.
作者
张海桢
成源源
何泉
ZHANG Haizhen;CHENG Yuanyuan;HE Quan(Department of Gastroenterology of the Fourth People’s Hospital of Shangqiu City,Shangqiu 476000 Henan,China)
出处
《中国民康医学》
2024年第7期44-47,共4页
Medical Journal of Chinese People’s Health
关键词
腹泻型
肠易激综合征
双歧杆菌四联活菌片
洛哌丁胺
炎性因子
肠道菌群
Diarrhea-predominant
Irritable bowel syndrome
Bifidobacterium quadruple viable tablets
Loperamide
Inflammatory factor
Intestinal flora
